非小细胞肺癌吉西他滨诱导化疗后≥2级放射性肺炎的危险因素
该研究纳入接受吉西他滨或多西他赛诱导化疗后放疗的NSCLC患者,吉西他滨组≥2级放射性肺炎发生率高于多西他赛组(25.5% vs 13.2%,P=0.005)。多因素分析仅肺V30是≥2级放射性肺炎的预测因子(P=0.03),低风险组(肺V5≤44%、V20≤24%、V30≤14.2%、MLD≤1226 cGy)发生率仅9.4%。
要点
- 吉西他滨诱导化疗后胸部放疗的≥2级放射性肺炎发生率高于多西他赛。
- 肺V30是多因素分析中唯一显著的≥2级放射性肺炎预测因子。
- 满足肺V5≤44%、V20≤24%、V30≤14.2%且MLD≤1226 cGy的低风险组发生率仅9.4%。
核心结论
- NSCLC患者胸部放疗前接受吉西他滨化疗与较高的≥2级放射性肺炎发生率相关,肺V30是最佳预测因子。
主要发现
- 吉西他滨组≥2级放射性肺炎发生率为25.5%,多西他赛组为13.2%(P=0.005)。
- 肺V5、V20、V30和MLD的最佳截断值分别为44%(AUC=0.593)、24%(AUC=0.607)、14.2%(AUC=0.622)和1226 cGy(AUC=0.626)。
- 多因素分析仅肺V30被确定为≥2级放射性肺炎的预测因子(P=0.03)。
- 吉西他滨诱导化疗患者中,低风险组(肺V5≤44%、V20≤24%、V30≤14.2%且MLD≤1226 cGy)的≥2级放射性肺炎发生率仅9.4%。
关键数值与推荐
- 肺V5最佳截断值44%(AUC=0.593),V20为24%(AUC=0.607),V30为14.2%(AUC=0.622),MLD为1226 cGy(AUC=0.626)。
- 低风险定义:肺V5≤44%、V20≤24%、V30≤14.2%且MLD≤1226 cGy,该组≥2级放射性肺炎发生率为9.4%。
临床怎么用
- 对NSCLC患者胸部放疗前使用吉西他滨诱导化疗时,应关注≥2级放射性肺炎风险并参考肺V30等剂量体积参数评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To observe the risk factors affecting the occurrence of RP after gemcitabine-based induction chemotherapy. METHODS: Between January 2010 and December 2017, patients with NSCLC received gemcitabine or docetaxel chemotherapy, followed by radiotherapy at Zhejiang cancer hospital were enrolled in this study. Patients were treated with gemcitabine or docetaxel induction chemotherapy, followed by radiotherapy or concurrent chemoradiotherapy. Acute radiation pneumonitis was scored post chemoradiotherapy. RESULTS: One hundred and eighty-four patients with NSCLC were included in the gemcitabine group and 144 in the docetaxel group. The gemcitabine group experienced a higher incidence of grade ≥ 2 RP, compared with docetaxel group (25.5% Vs. 13.2%, P = 0.005). The optimal cutoff values of lung V5, V20, V30 and MLD were set at 44% (AUC [area under the curve] = 0.593), 24% (AUC = 0.607), 14.2% (AUC = 0.622) and 1226 cGy (AUC = 0.626). On multivariate analysis, only lung V30 was identified as a predictor for grade ≥ 2 RP (P = 0.03). The grade ≥ 2 RP rate was only 9.4% for the low-risk group (Lung V5 ≤ 44%, V20 ≤ 24%, V30 ≤ 14.2%, and MLD ≤ 1226 cGy) in patients received gemcitabine induction chemotherapy. CONCLUSIONS: Gemcitabine chemotherapy before thoracic radiotherapy in NSCLC patients was related to a higher incidence of grade ≥ 2 RP, compared with docetaxel chemotherapy. The Lung dose-volume variable V30 was the best predictor of grade ≥ 2 RP.
引用
- Sheng L, Cui X, Cheng L, et al. Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer. Radiat Oncol. 2019. PMID: 31842910. doi:10.1186/s13014-019-1440-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。